FIRST-IN-HUMAN, SINGLE- AND MULTIPLE-ASCENDING-DOSE, FOOD-EFFECT, AND ABSOLUTE BIOAVAILABILITY TRIALS TO ASSESS THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF PRITELIVIR, A NONNUCLEOSIDE HELICASE-PRIMASE INHIBITOR AGAINST HERPES SIMPLEX VIRUS IN HEALTHY SUBJECTS
Kropeit D., Bonsmann S., von Richter O., McCormick D., Pausch J., Sumner M., Birkmann A., Zimmermann H., Rübsamen-Schaeff H.
Clin Pharmacol Drug Dev. 2023 Mar 1. doi: 10.1002/cpdd.1241
DISCOVERY, CHEMISTRY, AND PRECLINICAL DEVELOPMENT OF PRITELIVIR, A NOVEL TREATMENT OPTION FOR ACYCLOVIR-RESISTANT HERPES SIMPLEX VIRUS INFECTIONS
Birkmann, A., Bonsmann, S., Kropeit, D., Pfaff, T., Rangaraju, M., Sumner, M., Timmler, B., Zimmermann, H., Buschmann, H., & Ruebsamen-Schaeff, H.
J Med Chem . 2022 Oct 6. doi: 10.1021/acs.jmedchem.2c00668
THE EFFECT OF ORAL LETERMOVIR ADMINISTRATION ON THE PHARMACOKINETICS OF A SINGLE ORAL DOSE OF P-GLYCOPROTEIN SUBSTRATE DIGOXIN IN HEALTHY VOLUNTEERS
Scheuenpflug J, Kropeit D, Erb-Zohar K, Theis JGW, Stobernack HP, McCormick D, Zimmermann H, Rübsamen-Schaeff H..
Clin Pharmacol Drug Dev. 2022 Jan;11(1):6-15. doi: 10.1002/cpdd.1043. Epub 2021 Nov 23. PMID: 34812580..
INTERACTION MODE OF THE NOVEL MONOBACTAM AIC499 TARGETING PENICILLIN BINDING PROTEIN 3 OF GRAM-NEGATIVE BACTERIA
Freischem S, Grimm I, López-Pérez A, Willbold D, Klenke B, Vuong C, Dingley AJ, Weiergräber OH. Interaction Mode of the Novel Monobactam AIC499 Targeting Penicillin Binding Protein 3 of Gram-Negative Bacteria.
Biomolecules. 2021 Jul 19;11(7):1057. doi: 10.3390/biom11071057. Erratum in: Biomolecules. 2021 Dec 21;12(1): PMID: 34356681; PMCID: PMC8301747.
CLINICAL OUTCOMES OF HOSPITALISED PATIENTS WITH CATHETER-ASSOCIATED URINARY TRACT INFECTION IN COUNTRIES WITH A HIGH RATE OF MULTIDRUG-RESISTANCE: THE COMBACTE-MAGNET RESCUING STUDY.
Gomila A, Carratalà J, Eliakim-Raz N, Shaw E, Tebé C, Wolkewitz M, Wiegand I, Grier S, Vank C, Cuperus N, Van den Heuvel L, Vuong C, MacGowan A, Leibovici L, Addy I, Pujol M; RESCUING Study Group and Study Sites.
Antimicrob Resist Infect Control. 2019 Dec 3;8:198. doi: 10.1186/s13756-019-0656-6. eCollection 2019
RISK FACTORS FOR TREATMENT FAILURE AND MORTALITY AMONG HOSPITALIZED PATIENTS WITH COMPLICATED URINARY TRACT INFECTION: A MULTICENTER RETROSPECTIVE COHORT STUDY (RESCUING STUDY GROUP).
Eliakim-Raz N, Babitch T, Shaw E, Addy I, Wiegand I, Vank C, Torre-Vallejo L, Joan-Miquel V, Steve M, Grier S, Stoddart M, Nienke C, Leo VDH, Vuong C, MacGowan A, Carratalà J, Leibovici L, Pujol M; RESCUING Study Group.
Clin Infect Dis. 2019 Jan 1;68(1):29-36. doi: 10.1093/cid/ciy418.
NOVEL NON-HETEROARYLPYRIMIDINE (HAP) CAPSID ASSEMBLY MODIFIERS HAVE A DIFFERENT MODE OF ACTION FROM HAPS IN VITRO.
Corcuera A, Stolle K, Hillmer S, Seitz S, Lee JY, Bartenschlager R, Birkmann A, Urban A.
Antiviral Res. 2018 Oct;158:135-142. doi: 10.1016/j.antiviral.2018.07.011.
Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial.
Wald A, Timmler B, Magaret A, Warren T, Tyring S, Johnston C, Fife K, Selke S, Huang ML, Stobernack HP, Zimmermann H, Corey L, Birkmann A, Ruebsamen-Schaeff H.
JAMA. 2016 Dec 20;316(23):2495-2503. doi: 10.1001/jama.2016.18189.
NO EVIDENCE OF PRITELIVIR RESISTANCE AMONG HERPES SIMPLEX VIRUS TYPE 2 ISOLATES AFTER 4 WEEKS OF DAILY THERAPY.
Edlefsen PT, Birkmann A, Huang ML, Magaret CA, Kee JJ, Diem K, Goldner T, Timmler B, Stoelben S, Ruebsamen-Schaeff H, Zimmermann H, Warren T, Wald A, Corey L.
J Infect Dis. 2016 Jul 15;214(2):258-64. doi: 10.1093/infdis/jiw129.
MATHEMATICAL MODELING OF HERPES SIMPLEX VIRUS-2 SUPPRESSION WITH PRITELIVIR PREDICTS TRIAL OUTCOMES.
Schiffer JT, Swan DA, Magaret A, Corey L, Wald A, Ossig J, Ruebsamen-Schaeff H, Stoelben S, Timmler B, Zimmermann H, Melhem MR, Van Wart SA, Rubino CM, Birkmann A.
Sci Transl Med. 2016 Feb 3;8(324):324ra15. doi: 10.1126/scitranslmed.aad6654.